Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Schmitt, Clemens Prof. Dr. (1) Specker, Edgar Dr. (1) von Kries, Jens Peter Dr. (1) Wollert-Wulf, Brigitte (1) (-) Janz, Martin Dr. (5) (-) Mathas, Stephan Dr. (8) (-) Biologie maligner Lymphome (10) Genetik und Genomik von Herz- Kreislauferkrankungen (1) Integrative Vaskuläre Biologie (1) Molekulare Immunologie und Gentherapie (9) Systembiologie von Gen-regulatorischen Elementen (1) Translational Bioinformatics (1) Tumorgenetik und zelluläre Stressantworten (1) 1999 (1) 2000 (1) 2001 (1) 2002 (5) 2003 (3) 2004 (3) 2005 (3) 2006 (5) 2007 (4) 2008 (4) 2009 (4) 2010 (3) 2011 (4) 2012 (2) 2013 (3) 2014 (2) (-) 2015 (5) 2016 (3) (-) 2017 (5) 2018 (1) 2019 (2) 2020 (6) 2021 (3) 2022 (7) 2024 (2) 10 Ergebnisse: Active Filter: Janz, Martin Dr.Mathas, Stephan Dr.Biologie maligner Lymphome20152017 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Mai 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz 01. März 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas 01. Dezember 2017 / Lancet Oncol Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group D.A. Eichenauer A. Plütschow S. Kreissl M. Sökler J.C. Hellmuth J. Meissner S. Mathas M.S. Topp K. Behringer W. Klapper G. Kuhnert M. Dietlein C. Kobe M. Fuchs V. Diehl A. Engert P. Borchmann 13. Dezember 2017 / J Neurosci Graded elevation of c-Jun in Schwann cells in vivo: gene dosage determines effects on development, remyelination, tumorigenesis, and hypomyelination S.V. Fazal J.A. Gomez-Sanchez L.J. Wagstaff N. Musner G. Otto M. Janz R. Mirsky K.R. Jessen 01. April 2017 / Br J Haematol Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012) N. Baras S. Dahm J. Haberland M. Janz K. Emrich K. Kraywinkel A. Salama 01. Januar 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz 01. März 2017 / Leukemia Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma K.D. Wurster F. Hummel J. Richter M. Giefing S. Hartmann M.L. Hansmann S. Kreher K. Köchert D. Krappmann W. Klapper M. Hummel S.S. Wenzel G. Lenz M. Janz B. Dörken R. Siebert S. Mathas 11. April 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert 01. Juni 2015 / Front Biosci The origins of ALK translocations V. Roukos S. Mathas 05. Januar 2017 / Blood Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma J. Du M. Neuenschwander Y. Yu J.H.M. Däbritz N.R. Neuendorff K. Schleich A. Bittner M. Milanovic G. Beuster S. Radetzki E. Specker M. Reimann F. Rosenbauer S. Mathas P. Lohneis M. Hummel B. Dörken J.P. von Kries S. Lee C.A. Schmitt
01. Mai 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz
01. März 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas
01. Dezember 2017 / Lancet Oncol Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group D.A. Eichenauer A. Plütschow S. Kreissl M. Sökler J.C. Hellmuth J. Meissner S. Mathas M.S. Topp K. Behringer W. Klapper G. Kuhnert M. Dietlein C. Kobe M. Fuchs V. Diehl A. Engert P. Borchmann
13. Dezember 2017 / J Neurosci Graded elevation of c-Jun in Schwann cells in vivo: gene dosage determines effects on development, remyelination, tumorigenesis, and hypomyelination S.V. Fazal J.A. Gomez-Sanchez L.J. Wagstaff N. Musner G. Otto M. Janz R. Mirsky K.R. Jessen
01. April 2017 / Br J Haematol Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012) N. Baras S. Dahm J. Haberland M. Janz K. Emrich K. Kraywinkel A. Salama
01. Januar 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz
01. März 2017 / Leukemia Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma K.D. Wurster F. Hummel J. Richter M. Giefing S. Hartmann M.L. Hansmann S. Kreher K. Köchert D. Krappmann W. Klapper M. Hummel S.S. Wenzel G. Lenz M. Janz B. Dörken R. Siebert S. Mathas
11. April 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert
05. Januar 2017 / Blood Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma J. Du M. Neuenschwander Y. Yu J.H.M. Däbritz N.R. Neuendorff K. Schleich A. Bittner M. Milanovic G. Beuster S. Radetzki E. Specker M. Reimann F. Rosenbauer S. Mathas P. Lohneis M. Hummel B. Dörken J.P. von Kries S. Lee C.A. Schmitt